GENI.LSE Genincode PLC
- Market cap
- GBX 4.67M
- P/E
- -
- P/B
- 2.41x
- ROE
- -488.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is GENI.LSE undervalued?
Graham numberThe Graham number of Genincode PLC cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Genincode PLC fundamental analysis
No fundamental analysis for Genincode PLC yet.
Genincode PLC stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Genincode PLC
GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of familial hypercholesterolemia with further coronary risk stratification of the pat…
Full company profileGenincode PLC financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Genincode PLC annual financial statements
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 1.92M | 961K | 1.15M | 1.43M | 2.16M | 2.70M | 3.08M | 4.50M |
| Gross Profit | 1.04M | 523K | 593K | 632K | 1.02M | 1.43M | 1.54M | 1.88M |
| Operating Income | -497K | -1.05M | -3.53M | -5.90M | -7.15M | -5.13M | -5.89M | -10.2M |
| EBITDA | -483K | -1.03M | -4.10M | -5.57M | -6.65M | -4.69M | -5.63M | -9.90M |
| Net Income | -404K | -1.17M | -4.14M | -5.56M | -7.02M | -4.43M | -5.71M | -10.1M |
| EPS | -6.03 | -0.01 | -0.08 | -0.06 | -0.07 | -0.03 | -0.02 | -0.02 |
| Balance Sheet | ||||||||
| Total Assets | 489K | 2.42M | 15.2M | 11.8M | 4.19M | 2.66M | 2.38M | 3.53M |
| Total Liabilities | 929K | 563K | 1.49M | 3.90M | 2.90M | 1.54M | 2.25M | 1.47M |
| Shareholders' Equity | -440K | 1.86M | 13.7M | 7.90M | 1.29M | 1.13M | 124K | 2.06M |
| Cash & Short-term Investments | 85.1K | 2.00M | 14.6M | 9.75M | 2.53M | 1.17M | 895K | 2.05M |
| Total Debt | 331K | - | - | 354K | 299K | 234K | 146K | 98.0K |
| Cash Flow | ||||||||
| Operating Cash Flow | -191K | -1.04M | -3.02M | -3.76M | -7.51M | -5.17M | -4.07M | -12.1M |
| Capital Expenditure | 124K | 68.3K | 145K | 849K | 38.0K | 49.0K | 44.0K | 16.0K |
| Free Cash Flow | -314K | -1.11M | -3.17M | -4.61M | -7.54M | -5.22M | -4.11M | -12.1M |
| Ratios | ||||||||
| ROE | - | -62.7% | -30.2% | -70.4% | -544.3% | -393.4% | -4,600.8% | -488.7% |
| ROA | -82.5% | -48.1% | -27.2% | -47.1% | -167.6% | -166.5% | -240.0% | -285.7% |
| Net Profit Margin | -21.0% | -121.4% | -358.9% | -388.7% | -324.8% | -164.2% | -185.5% | -223.9% |
| Debt to Equity | - | - | - | 0.04x | 0.23x | 0.21x | 1.18x | 0.05x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Genincode PLC dividends
Genincode PLC has not paid dividends in the last 7 fiscal years.
Who owns Genincode PLC
- Insiders 32.67%
- Institutions 22.13%
- Public & others 45.20%
- Shares outstanding 753M
- Free float 366M
Genincode PLC company profile
- Company name
- Genincode PLC
- Ticker
- GENI.LSE
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 44
- Fiscal year end
- December
- Address
- One St. Peters Square, Manchester, United Kingdom, M2 3DE
- Phone
- 44 1865 676 125
- Website
- genincode.com
About Genincode PLC
GENinCode Plc engages in the development and commercialization of clinical genetic tests for predictive analysis of risk to a patient's health based on genes in the United Kingdom, Spain, Italy, the United States, Germany, and internationally. The company offers CARDIO inCode Score, a genetic test to evaluate the risk of coronary heart disease; LIPID inCode, a genetic test for the diagnosis of familial hypercholesterolemia with further coronary risk stratification of the patient; and SUDD inCode, a genetic diagnostic test for familial heart diseases, such as cardiomyopathies, channelopathies, and aortopathies related with sudden cardiac death syndrome. It also provides THROMBO inCode, a genetic test for the diagnosis of hereditary thrombophilia and for assessing the patient's risk of thrombosis; THROMBO inCode reproductive health, a genetic test that evaluates the impact of hereditary thrombophilia in patients with repeated miscarriages; and risk of ovarian cancer algorithm test product. In addition, the company is involved in Medical and scientific research activities. GENinCode Plc was incorporated in 2018 and is based in Manchester, the United Kingdom.
Genincode PLC management
3- Mr. Matthew Heaton WallsCo-Founder, CEO & Director · born 1964
- Mr. Jordi Puig GilberteCo-Founder, COO & Director · born 1975
- Mr. Paul Andrew Peter FoulgerCFO, Company Secretary & Director · born 1969